Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

Medical Journal of Australia

Volumn 179, Issue 8, 2003, Pages 403-407

  Kerr, Stephen J ^a   Mant, Andrea ^b   Horn, Fiona E ^c   McGeechan, Kevin ^c   Sayer, Geoffrey P ^c  

^a National Prescribing Service Limited   (Australia)

^b South Eastern Sydney and Illawarra Area Health Service   (Australia)

^c Health Communication Network   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CELECOXIB; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MELOXICAM; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; TRAMADOL; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; AUSTRALIA; BACKACHE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; FLUID RETENTION; GENERAL PRACTICE; GENERAL PRACTITIONER; GOUT; HUMAN; INJURY; ISCHIALGIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PAIN; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SIDE EFFECT; SPONDYLOSIS; SPRAIN; STATISTICAL ANALYSIS; TENDINITIS;

EID: 0142198884     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05616.x     Document Type: Article

References (24)

1. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
2. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-314.
3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
5. Davies JA. Arthritis drug under siege. The Age (Melbourne) 6 Feb 2001; Sect: News: 1.
6. Your reports at work - Drug safety in Australia. Aust Adverse Drug React Bull 2001; 20(4): 15-16.
7. Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: The triple whammy revisited. Med J Aust 2000; 173: 274.
8. Sayer GP, McGreechan K, Kemp A, et al. The General Practice Research Network: The capabilities of an electronic patient management system for longitudinal patient data. Pharmacoepidemiol Drug Safety 2003; 12: 483-489
9. Therapeutic Guidelines: Analgesic. 4th ed. Melbourne: Therapeutic Guidelines Limited; 2002.
10. SAS. Version 8 [computer program]. Cary, NC: SAS Institute Inc, 2002.
11. Mansfield P. Healthy scepticism about Pfizer and Searle's promotion of celecoxib in Australia. Healthy Skepticism Int Ed. March/April 2000; 18 (3/4). Available at: www.healthyskepticism.org/editions/IN0004.htm (accessed Dec 2002).
12. Davies J-A, Foley B. A drug that was sold on hope. The Age (Melbourne) 10 Feb 2001; Sect: News: 1.
13. Anderson WB. The media battle between Celebrex and Vioxx: Influencing media coverage but not content. Public Relat Rev 2001; 27: 449-460.
14. Maetzel A, Krahn MD, Naglie G. Economic assessment: Celecoxib and rofecoxib for patients with osteoarthritis and rheumatoid arthritis. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2002. Report No.; Technology Overview Number 6. Available at: www.ccohta.ca/ (accessed May 2003).
15. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: National Institute for Clinical Excellence; July 2001. Report No.: NICE Technology Appraisal Guidance Number 27. Available at: www.nice.org.uk/pdf/coxiifullguidance.pdf (accessed May 2003).
16. Jones R. Efficacy and safety of COX 2 inhibitors. BMJ 2002; 325: 607-608.
17. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
18. Lassere M, Johnson K. The power of the protocol. Lancet 2002; 360: 1620-1622.
19. Lipsky LP, Abramson SB, Crofford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25: 2298-2303.
20. The Australian COX-2-Specific Inhibitor (CSI) Prescribing Group. Considerations for the safe prescribing and use of COX-2-specific inhibitors [position statement]. Med J Aust 2002; 176: 328-331.
21. Cutts C, LaCaze A, Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Br J Clin Pharmacol 2002; 54: 522-527.
22. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993; 342: 658-661.
23. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220.
24. National Medicines Policy 2000. Canberra: Commonwealth Department of Health and Aged Care; 1999.